China Needs To Align With International Standards To Grow Its Biologics Industry: BIO
This article was originally published in PharmAsia News
On the plus side, China has pledged policy support and hefty funding to build up its biologics industry. However, weak intellectual property protection, a challenging regulatory environment and market access and profitability issues still deter industry investment, according to the Biotechnology Industry Organization.
You may also be interested in...
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.
Prices of direct acting hepatitis C drugs are down by 85% in China, with cancer and antidiabetes therapy costs cut by 65% and drug makers are rushing to celebrate. Scrip delves into the considerations behind the low prices and whether industry's excitement is a bit premature.
Rapid changes in China prompt many pharma companies to shuffle strategies and accelerate personal changes. BMS is getting a new country GM, Pfizer Biopharma China GM is departing and Takeda BU head is stepping down.